Literature DB >> 20036832

WHAT do viruses BET on?

Magdalena Weidner-Glunde1, Matthias Ottinger, Thomas F Schulz.   

Abstract

The bromodomain and ET domain (BET) proteins belong to a group of bromodomain proteins and bind acetylated histones. Two of the currently known members of this protein family were implicated in transcriptional regulation. The two most studied BET proteins Brd2 and Brd4 have been shown to bind to viral proteins of herpesviruses and papillomaviruses. These pathogens often take advantage of the cellular function of the BET proteins and exploit it for their own purposes. In some cases though, viral proteins were shown to adapt BET proteins to new virus specific functions. Additionally some retroviruses seem to encode proteins that mimic Brd4 functions and hijack Brd4-associated protein complexes to use them for their own transcription.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20036832     DOI： 10.2741/3632

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN： 2768-6698


  18 in total

1.  Tools and landscapes of epigenetics.

Authors:  Alexander Tarakhovsky
Journal:  Nat Immunol       Date:  2010-07       Impact factor: 25.606

2.  BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.

Authors:  Mary A Morse; Karla K Balogh; Sarah A Brendle; Colin A Campbell; Mao X Chen; Rebecca C Furze; Isobel L Harada; Ian D Holyer; Umesh Kumar; Kevin Lee; Rab K Prinjha; Martin Rüdiger; Jonathan T Seal; Simon Taylor; Jason Witherington; Neil D Christensen
Journal:  Antiviral Res       Date:  2018-04-11       Impact factor: 5.970

Review 3.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition.

Authors:  Junwei Shi; Christopher R Vakoc
Journal:  Mol Cell       Date:  2014-06-05       Impact factor: 17.970

4.  The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3.

Authors:  Shaila Rahman; Mathew E Sowa; Matthias Ottinger; Jennifer A Smith; Yang Shi; J Wade Harper; Peter M Howley
Journal:  Mol Cell Biol       Date:  2011-05-09       Impact factor: 4.272

5.  Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration.

Authors:  Saumya Shree Gupta; Tobias Maetzig; Goedele N Maertens; Azar Sharif; Michael Rothe; Magdalena Weidner-Glunde; Melanie Galla; Axel Schambach; Peter Cherepanov; Thomas F Schulz
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

6.  BET proteins promote efficient murine leukemia virus integration at transcription start sites.

Authors:  Amit Sharma; Ross C Larue; Matthew R Plumb; Nirav Malani; Frances Male; Alison Slaughter; Jacques J Kessl; Nikolozi Shkriabai; Elizabeth Coward; Sriram S Aiyer; Patrick L Green; Li Wu; Monica J Roth; Frederic D Bushman; Mamuka Kvaratskhelia
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

7.  The Brd4 acetyllysine-binding protein is involved in activation of polyomavirus JC.

Authors:  Hassen S Wollebo; Anna Bellizzi; Dominique H Cossari; Julian Salkind; Mahmut Safak; Martyn K White
Journal:  J Neurovirol       Date:  2016-03-23       Impact factor: 2.643

Review 8.  Bromodomains as therapeutic targets.

Authors:  Susanne Muller; Panagis Filippakopoulos; Stefan Knapp
Journal:  Expert Rev Mol Med       Date:  2011-09-13       Impact factor: 5.600

9.  Interaction of gamma-herpesvirus genome maintenance proteins with cellular chromatin.

Authors:  Nouman Mughal; Giuseppe Coppotelli; Simone Callegari; Stefano Gastaldello; Maria G Masucci
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

10.  The Epstein-Barr virus nuclear antigen-1 reprograms transcription by mimicry of high mobility group A proteins.

Authors:  Giuseppe Coppotelli; Nouman Mughal; Simone Callegari; Ramakrishna Sompallae; Laia Caja; Martijn S Luijsterburg; Nico P Dantuma; Aristidis Moustakas; Maria G Masucci
Journal:  Nucleic Acids Res       Date:  2013-01-28       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.